Defusing US Opioid Crisis Offers Orexo "Strong Growth Potential" Says CEO

 
• By Sten Stovall

The CEO of Swedish addiction and pain specialist Orexo tells Scrip its top drug Zubsolv will grow strongly in coming years to address the opioid crisis in the US, and that revenues will be further boosted by novel pipeline therapies likely to be commercialized in coming years.

USA_Stethoscope
Orexo believes US will increasingly turn to its novel opioid dependence therapies • Source: Shutterstock

More from Strategy

More from Business